146 related articles for article (PubMed ID: 10731041)
1. Roles of group II metabotropic glutamate receptors in modulation of seizure activity.
Kłodzińska A; Bijak M; Chojnacka-Wójcik E; Kroczka B; Swiader M; Czuczwar SJ; Pilc A
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):283-8. PubMed ID: 10731041
[TBL] [Abstract][Full Text] [Related]
2. Selective group II glutamate metabotropic receptor agonist LY354740 attenuates pentetrazole- and picrotoxin-induced seizures.
Kłodzińska A; Chojnacka-Wójcik E; Pilc A
Pol J Pharmacol; 1999; 51(6):543-5. PubMed ID: 10817535
[TBL] [Abstract][Full Text] [Related]
3. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
Helton DR; Tizzano JP; Monn JA; Schoepp DD; Kallman MJ
J Pharmacol Exp Ther; 1998 Feb; 284(2):651-60. PubMed ID: 9454811
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
[TBL] [Abstract][Full Text] [Related]
5. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
Fell MJ; Perry KW; Falcone JF; Johnson BG; Barth VN; Rash KS; Lucaites VL; Threlkeld PG; Monn JA; McKinzie DL; Marek GJ; Svensson KA; Nelson DL
J Pharmacol Exp Ther; 2009 Dec; 331(3):1126-36. PubMed ID: 19755662
[TBL] [Abstract][Full Text] [Related]
7. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
Tizzano JP; Griffey KI; Schoepp DD
Pharmacol Biochem Behav; 2002 Sep; 73(2):367-74. PubMed ID: 12117591
[TBL] [Abstract][Full Text] [Related]
8. Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist.
Schoepp DD; Johnson BG; Wright RA; Salhoff CR; Monn JA
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):175-80. PubMed ID: 9750002
[TBL] [Abstract][Full Text] [Related]
9. Anticonvulsant effects of phencynonate hydrochloride and other anticholinergic drugs in soman poisoning: neurochemical mechanisms.
Wang YA; Zhou WX; Li JX; Liu YQ; Yue YJ; Zheng JQ; Liu KL; Ruan JX
Life Sci; 2005 Nov; 78(2):210-23. PubMed ID: 16154160
[TBL] [Abstract][Full Text] [Related]
10. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
[TBL] [Abstract][Full Text] [Related]
11. The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats.
Koltunowska D; Gibula-Bruzda E; Kotlinska JH
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():242-9. PubMed ID: 23623810
[TBL] [Abstract][Full Text] [Related]
12. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.
Konieczny J; Ossowska K; Wolfarth S; Pilc A
Naunyn Schmiedebergs Arch Pharmacol; 1998 Oct; 358(4):500-2. PubMed ID: 9826074
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.
Monn JA; Valli MJ; Massey SM; Wright RA; Salhoff CR; Johnson BG; Howe T; Alt CA; Rhodes GA; Robey RL; Griffey KR; Tizzano JP; Kallman MJ; Helton DR; Schoepp DD
J Med Chem; 1997 Feb; 40(4):528-37. PubMed ID: 9046344
[TBL] [Abstract][Full Text] [Related]
14. Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice.
Popik P; Kozela E; Pilc A
Br J Pharmacol; 2000 Jul; 130(6):1425-31. PubMed ID: 10903986
[TBL] [Abstract][Full Text] [Related]
15. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740.
Procaccini C; Maksimovic M; Aitta-Aho T; Korpi ER; Linden AM
Neuroscience; 2013 Oct; 250():189-200. PubMed ID: 23867766
[TBL] [Abstract][Full Text] [Related]
16. Effects of the group II metabotropic glutamate receptor agonist, LY354740 on schedule-controlled behaviour in rats.
Moore NA; Rees G; Monn JA
Behav Pharmacol; 1999 May; 10(3):319-25. PubMed ID: 10780246
[TBL] [Abstract][Full Text] [Related]
17. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
[TBL] [Abstract][Full Text] [Related]
18. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.
Linden AM; Greene SJ; Bergeron M; Schoepp DD
Neuropsychopharmacology; 2004 Mar; 29(3):502-13. PubMed ID: 14694349
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
20. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
Krystal JH; Abi-Saab W; Perry E; D'Souza DC; Liu N; Gueorguieva R; McDougall L; Hunsberger T; Belger A; Levine L; Breier A
Psychopharmacology (Berl); 2005 Apr; 179(1):303-9. PubMed ID: 15309376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
